Nectar Lifesciences Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

Nectar Lifesciences' board approved the financial results for the quarter. Consolidated revenue stood at Rs 280.67 Cr, with a net loss of Rs 63.23 Cr (EPS Rs -2.82). In major strategic moves, the company announced the sale of its API & formulations business for Rs 1,270 Cr and menthol assets for Rs 20 Cr to Ceph Lifesciences. The 30th Annual General Meeting is scheduled for September 29. Key decisions also included the re-appointment of Director Sanjiv Goyal, appointment of Secretarial Auditors for five years, and Cost Auditors for FY26, all subject to AGM approval. New Articles of Association will also be adopted.